diclofenac + calcitriol

Diclofenac + calcitriol is a topical combination therapy consisting of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), and calcitriol, the active form of vitamin D3. This combination has been investigated primarily for the treatment and chemoprevention of superficial basal cell carcinoma (sBCC) and other non-melanoma skin cancers. Diclofenac acts by inhibiting cyclooxygenase enzymes, reducing prostaglandin synthesis involved in inflammation and tumorigenesis. Calcitriol modulates cellular proliferation, differentiation, and apoptosis through activation of the vitamin D receptor pathway. The combined use targets multiple signaling pathways implicated in skin carcinogenesis, offering potential additive or synergistic effects compared to monotherapy[1][2][4][5].